Esanex

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Esanex sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Esanex: 10 sponsored US clinical trials, none currently recruiting.

Esanex sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 3 trials.

Top-decile sponsor footprint

Esanex ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

TERMINATED Phase 1

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

NCT02973399
TERMINATED Phase 2

Study of SNX-5422 in TP53 Null Cancers

NCT02612285
COMPLETED Phase 1

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

NCT02063958
COMPLETED Phase 1

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

NCT01635712
COMPLETED Phase 1

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

NCT01892046
TERMINATED Phase 1

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

NCT01848756
COMPLETED Phase 1

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

NCT01851096
COMPLETED Phase 1

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

NCT00647764
COMPLETED Phase 1

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

NCT00595686
COMPLETED Phase 1

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

NCT00506805

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 1

Therapeutic Areas

Cancer 3
Hematologic Neoplasms 1

How the Esanex early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Cancer (3 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Esanex: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Esanex sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share EsanexAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Esanex sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Esanex sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Esanex page

10 registered trials is a research-attention snapshot, not an endorsement of Esanex or any single study.

  • None of Esanex's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Cancer is the condition Esanex studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Esanex pipeline card: 10 registered trials from official public datasets.Report a data error.